Clinical trials: End-Stage Kidney Disease
End Stage Renal Disease
Effect of Changes in Dialysate Bicarbonate on Serum Calcification Propensity and Calciprotein Particles in Hemodialysis Patients
This is a single-center, prospective, proof-of-priciple, pilot study in 24 end-stage renal disease patients on chronic hemodiaysis.
- Trial name
- D-Bic-T50-HD (NCT06084858)
- Testing
- Dialysate bicarbonate modification
- Where
- Austria
- Volunteers
- 26 people
- Sponsor
- Prim. Priv. Doz. Dr. Daniel Cejka
End-Stage Renal Disease (ESRD)
Aluminum and Auditory Function in ESRD
Hearing impairment either clinical or subclinical is a characteristic of some renal disease patients. The hearing impairment could be result from specific etiologies or chronic renal failure itself.
- Trial name
- NCT00243958
- Where
- 2 sites in Taiwan
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Kidney Failure, Chronic, End-Stage Renal Disease
Effect of Sevelamer on Glucose Tolerance and Insulin Sensitivity in Patients With Chronic Renal Failure (CKD)
The purpose of this study is to perform a randomized, controlled clinical trial to investigate if the phosphate binder sevelamer can improve insulin resistance and glucose handling in patients receiving maintenance hemodialysis.
- Conditions
- Kidney Failure, Chronic, End-Stage Renal Disease, Insulin Resistance, Hyperphosphatemia
- Trial name
- SIR (NCT00837655)
- Testing
- Sevelamer, Calcium carbonate
- Where
- 2 sites in Sweden
- Sponsor
- Karolinska Institutet
End-stage Renal Disease (ESRD)
A Study of Safety, PK, & PD of ISIS 416858 Administered Subcutaneously to Patients With End-Stage Renal Disease on Hemodialysis
Evaluation of safety, tolerability, PK and PD of ISIS 416858 in patients with end-stage renal disease (ESRD) receiving chronic hemodialysis.
- Trial name
- NCT02553889
- Testing
- ISIS 416858
- Where
- 8 sites in Canada
- Volunteers
- 49 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Coronary Disease, Fatty Acids, Unsaturated
123I-BMIPP SPECT Analysis for Decreasing Cardiac Events in Hemodialysis Patients
The aim of this multi-center study is to determine the applicability of BMIPP to diagnosing cardiac disease and to predicting the outcome of patients on hemodialysis.
- Conditions
- Coronary Disease, Fatty Acids, Unsaturated, Radioisotopes, Hemodialysis
- Trial name
- B-SAFE (NCT00586950)
- Where
- Japan
- Volunteers
- 1,000 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Chronic Renal Failure
Pulsatile Perfusion Preservation in Kidney Transplantation From Expanded Criteria Donors
Our hypothesis is that the Waters Medical® pulsatile perfusion machine (RM 3) is a way to improve delayed graft function (DGF) in marginal grafts, and some perfusion profiles (flow, pressure, resistance index, venous effluent pH)…
- Trial name
- IMPULSION (NCT01170910)
- Testing
- Static incubation, Pulsatile perfusion
- Where
- France
- Volunteers
- 162 people
- Sponsor
- Hospices Civils de Lyon
End-Stage Renal Disease
Effect of Different Hemodialysis Modality on Adiponectin,Vascular Function and Clinical Prognosis
Adiponectin, an adipose tissue derived protein, with anti-inflammatory properties that is secreted from adipose tissue, is associated with insulin resistance.
- Trial name
- NCT00155363
- Testing
- conventional artificial kidney (AK) vs. high flux AK
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
End-Stage Renal Disease
Association of FGF-23 and Parathyroid Hormone (PTH) in Dialysis Patients
The purpose of this study is to determine how levels of this newly-discovered hormone, called FGF-23, changes in the blood in response to a high calcium dialysis bath during a hemodialysis (HD) treatment, and how this relates to…
- Trial name
- NCT00477516
- Testing
- exposure to a high-calcium dialysate bath
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- James B. Wetmore, MD
Hyperphosphatemia, End Stage Renal Disease
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of the Effects of Ferric Citrate in Subjects With End Stage Renal Disease
The purpose of the study is to determine the effect and optimum dose and evaluate the safety of ferric citrate, administered three times daily (TID) immediately after meals for a total daily dose of 4 or 6 grams for 56 days, on…
- Conditions
- Hyperphosphatemia, End Stage Renal Disease, ESRD
- Trial name
- NCT01503736
- Testing
- ferric citrate
- Where
- 5 sites in Taiwan
- Volunteers
- 183 people
- Sponsor
- Panion & BF Biotech Inc.
Quality of Life
Comparison of Postoperative Early Period Quality of Life of Patients With Open and Robot Assisted Kidney Transplantation
The investigators aimed to investigate the quality of life in patients with end-stage renal disease who underwent open or robot-assisted renal transplantation.
- Trial name
- NCT04435171
- Testing
- Renal transplantation
- Where
- Turkey (Türkiye)
- Volunteers
- 129 people
- Sponsor
- Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Peritoneal Dialysis Complication, End Stage Kidney Disease
meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis
The primary aim of this study is to determine the safety and mechanisms of SGLT2 inhibition in individuals on peritoneal dialysis (PD) with residual kidney function (RKF).
- Conditions
- Peritoneal Dialysis Complication, End Stage Kidney Disease, Sodium-glucose Co-transporter-2 Inhibitors, Kidney Dysfunction
- Trial name
- CANARY (NCT05715814)
- Testing
- Empagliflozin 25 MG
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University Health Network, Toronto
Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell
Project to Improve Communication About Serious Illness - Pilot Study
This two-year pilot study will test whether a one-page "Jumpstart Form" will affect goals-of-care discussions in the hospital. This form will be provided to clinicians and will include patient-specific information about…
- Conditions
- Malignant Neoplasm, Leukemia, Lymphocytic, Chronic, B-Cell, Lung Disease Chronic, Congestive Heart Failure
- Trial name
- PICSI-P (NCT03746392)
- Testing
- Jumpstart Intervention
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- University of Washington
Chronic Renal Failure, Diabete Type 2
Symbiotics and Systemic Inflammation in Chronic Kidney Disease
Main objective: To assess the effectiveness of treatment with symbiotics on the chronic systemic inflammation observed in chronic renal failure 4 months after the start of treatment.
- Conditions
- Chronic Renal Failure, Diabete Type 2, Systemic Inflammation
- Trial name
- SISMIC (NCT04769687)
- Testing
- probiotic Vivomixx®, prebiotic Orafti®Synergy1
- Where
- France
- Volunteers
- 62 people
- Sponsor
- Centre Hospitalier Universitaire de Besancon
End-stage Renal Disease
Improved Induction and Maintenance Immunosuppression in Kidney Transplantation
This 2 x 2 sequential factorial study evaluates two potential improvements to the standard immunosuppression regimen used at the investigators' institution to prevent rejection of transplanted kidneys.
- Trial name
- NCT00556933
- Testing
- rabbit anti-thymocyte globulin - single dose, mycophenolate mofetil, rabbit anti-thymocyte globulin - 4 doses
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- University of Nebraska
CKD Stage 4, CKD Stage 5
Frailty, Cognitive Function and Health-related Quality of Life in Older Adults With Advanced Chronic Kidney Disease.
This observational study explores the impact of cognitive impairment and frailty in older adults with advanced chronic kidney disease ].
- Conditions
- CKD Stage 4, CKD Stage 5, Frailty, Cognitive Impairment
- Trial name
- NCT05705011
- Where
- Romania
- Volunteers
- 240 people
- Sponsor
- Grigore T. Popa University of Medicine and Pharmacy
CKD Stage 3, CKD Stage 4
A Single Arm sTudy to Evaluate the Effectiveness of EndoAVF in a Pre-dialysis Population (STEP Study)
This is an investigator-initiated post-marketing study that will evaluate use of the WaveLinQ system, a new and novel method of fistula creation using a percutaneous method in patients who require the creation of an arteriovenous…
- Conditions
- CKD Stage 3, CKD Stage 4, CKD Stage 5
- Trial name
- NCT04633304
- Testing
- EndoAVF System for endovascular AV fistula creation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- California Institute of Renal Research
End Stage Renal Disease
The Routine Use of SSRI's at the Initiation of End-stage Renal Disease Treatment (RoSIE)
In this study the investigators hypothesize that antidepressant therapy may improve the overall welling of patients with acute or chronic kidney disease when given around the time of starting chronic dialysis therapy.
- Trial name
- RoSIE (NCT02407821)
- Testing
- Escitalopram
- Where
- 3 sites in Canada
- Volunteers
- 25 people
- Sponsor
- University Health Network, Toronto
End-Stage Kidney Disease, Type 2 Diabetes Mellitus
Glucose Containing and Glucose Free Hemodialysate in Type 2 Diabetic Patients
The purpose of this study is to investigate differences in glycemia during the whole hemodialysis day and the whole freeday during hemodialysis, during the evening and the night after hemodialysis and at the same time intervals…
- Trial name
- NCT02009514
- Testing
- Glucose-containing compared to glucose-free hemodialysate
- Volunteers
- 10 people
- Sponsor
- Tampere University Hospital
End-Stage Renal Disease Requiring Haemodialysis
To Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN060 in ESRD Dialysis Patients
The primary objective of this study is to assess the safety and tolerability of KN060 in patients with end-stage renal disease on regular hemodialysis.
- Trial name
- NCT07201467
- Testing
- KN060
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Suzhou Alphamab Co., Ltd.
Myelofibrosis
PK of Pacritinib in Patients With Mild, Moderate, Severe Renal Impairment and ESRD Compared to Healthy Subjects
This is a Phase 1 open label, single dose, 5 parallel-group study in which a single 400 mg dose of pacritinib will be administered orally to patients with renal impairment (mild, moderate, severe, and patients with ESRD requiring…
- Trial name
- NCT02807077
- Testing
- Pacritinib
- Where
- 3 sites in Germany, Moldova and 1 more
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.